{"analyses":[{"ciLowerLimit":"0.84","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.45","paramType":"Hazard Ratio (HR)","paramValue":"0.95","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.5","upperLimit":"11.1","value":"10.6"},{"groupId":"OG001","lowerLimit":"9.5","upperLimit":"11.3","value":"10.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"559"},{"groupId":"OG001","value":"578"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"PFS will be measured from study entry until first documented progression or death from any cause. Time to event distributions will be estimated using the Kaplan-Meier method. PFS will be compared between Arm A and Arm B.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"OG000","title":"Arm A: FOLFOX or FOLFIRI + Bevacizumab"},{"description":"Patients receive cetuximab 400mg/m\\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\\^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"OG001","title":"Arm B: FOLFOX or FOLFIRI + Cetuximab"},{"description":"Patients receive cetuximab 400mg/m\\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\\^2 IV over 1 hour weekly thereafter. Also, patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"OG002","title":"Arm C: FOLFOX or FOLFIRI + Cetuximab + Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"All eligible KRAS wild type patients were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 5 years post-treatment","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}